$PRTA News
Last published 6d ago
- 6d agoPRTAPROTHENA CORP PUBLIC LTD CO - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPRTAProthena to Report Third Quarter 2026 Financial Results on November 5Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 2mo agoPRTAProthena to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its
- 3mo agoPRTAProthena Reports Second Quarter 2026 Financial Results and Business HighlightsBusiness WireNet cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end
- 3mo agoPRTAProthena to Report Second Quarter 2026 Financial Results on August 6Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 6mo agoPRTAProthena Reports First Quarter 2026 Financial Results and Business HighlightsBusiness WireNet cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net
- 6mo agoPRTAProthena to Report First Quarter 2026 Financial Results on May 7Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 6mo agoPRTAProthena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyBusiness WireCoramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical
- 7mo agoPRTAProthena Announces Leadership Team UpdatesBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates to its
- 7mo agoPRTAProthena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations
- 8mo agoPRTAProthena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with CardiomyopathyBusiness WireCoramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible
- 8mo agoPRTAProthena Announces up to $100 Million Share Repurchase PlanBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of
- 8mo agoPRTAProthena Fourth Quarter and Full Year 2025 Financial Results Conference CallPROTHENA CORP PUBLIC LTD COEarnings Call TranscriptsGood day ladies and gentlemen and welcome to the Procena Biosciences fourth quarter and full year 2025 financial results conference call. My name is Jeanne and I will be your coordinator for today. At this time all parti
- 8mo agoPRTAProthena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness WireNet cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4
- 9mo agoPRTAProthena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 11mo agoPRTAProthena Announces Board of Directors UpdateBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will
- 11mo agoPRTAProthena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025Business WireTDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena's CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease
- 1y agoPRTAProthena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHABusiness WireNovo Nordisk's Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo Nordisk as part of their up to
- 1y agoPRTAProthena to Report Third Quarter 2025 Financial Results on November 6Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 1y agoPRTAProthena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's DiseaseBusiness WireAnti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be
- 1y agoPRTAProthena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its
- 1y agoPRTAProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramBusiness WireAs previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical program established
- 1y agoPRTAProthena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with CardiomyopathyBusiness WireCoramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to
- 1y agoPRTAProthena Reports Second Quarter 2025 Financial Results and Business HighlightsBusiness WireNet cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash
- 1y agoPRTAProthena to Report Second Quarter 2025 Financial Results on August 4Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 1y agoPRTAProthena Announces Corporate RestructuringBusiness WireProthena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining
- 1y agoPRTAProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseBusiness WireData from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease Prasinezumab is a potential first-in-class
- 1y agoPRTAProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary EndpointBusiness WireBirtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the AFFIRM-AL
- 1y agoPRTAProthena Reports First Quarter 2025 Financial Results and Business HighlightsBusiness WireNet cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q 2025 from the
- 1y agoPRTAProthena to Report First Quarter 2025 Financial Results on May 8Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 1y agoPRTAProthena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness WireNet cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company
- 1y agoPRTAKuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law FirmGlobeNewswireNEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ:PRTA) breached their fiduciary
- 1y agoPRTAProthena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 1y agoPRTAProthena Announces Board of Directors UpdateBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Oleg Nodelman
- 1y agoPRTARoche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's DiseaseBusiness WirePADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints Prasinezumab continues to be well tolerated and no new safety signals were
- 1y agoPRTAProthena Reports Third Quarter 2024 Financial Results and Business HighlightsBusiness WireNet cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1
- 2y agoPRTAProthena to Report Third Quarter 2024 Financial Results on November 12Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 2y agoPRTAProthena Announces Leadership Team UpdatesBusiness WireChad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functions Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity at a large
- 2y agoPRTAProthena to Participate in Upcoming Healthcare ConferencesBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its
- 2y agoPRTAProthena Reports Second Quarter 2024 Financial Results and Business HighlightsBusiness WireNet cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months of 2024; quarter-end
- 2y agoPRTAProthena to Report Second Quarter 2024 Financial Results on August 8Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 2y agoPRTAProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationBusiness WireProthena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1
- 2y agoPRTAProthena Reports First Quarter 2024 Financial Results and Business HighlightsBusiness WireNet cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's
- 2y agoPRTAProthena to Report First Quarter 2024 Financial Results on May 8Business WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report
- 2y agoPRTAProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication
- 2y agoPRTAProthena to Participate in Upcoming Healthcare ConferencesBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its
- 2y agoPRTAProthena Appoints David Ford to Newly Created Chief People Officer PositionBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named
- 2y agoPRTAProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateBusiness WireProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of
- 2y agoPRTAProthena Corporation plc (PRTA) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPRTAProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness WireNet cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million The company